Digital health's point-solution era is giving way to broader platforms, and the cost-savings claims those platforms make to employers often don't hold up to methodological scrutiny.
News|Articles|June 1, 2026
Global leader in engagement with healthcare stakeholders
Author(s)Reverba Global
Advertisement
Reverba Global (formerly Health Perspectives Group) is a scientific engagement company that empowers biopharmaceutical companies to connect with patients and healthcare providers to improve health outcomes. Reverba Global’s Patient Experience Engine combines more than 20 years of patient engagement with proprietary scalable technology, compliance expertise and deep scientific knowledge to deliver real-time insights, from discovery through commercialization.
Explore Content Engagement Hub Resources from Reverba Global. Click Below.
- [Timeline]
Reverba Global by the numbers 20+ years of scientific patient engagement - [Framework]
reverbaBRIDGE ® Operational platform to enable engagement across functions - [Infographic]
Patient engagement Connecting throughout the product lifecycle - [V-Brochure]
Peer-to-peer mentoring Turning lived experience into measurable impact - [Checklist]
Compliance Experts in privacy and security - [V-Brochure]
Every clinical trial needs navigation ClinOps GPS™ - [Case Study]
Peer-to-peer mentoring case studies Onboarding, adherence, satisfaction - [Podcast]
MedAffairs evolves The bridge between Clinical and Commercial - [Case Study]
Patient Advisory Councils (PACs) Partnership for ongoing insights - [Fact Sheet]
Global engagement Broad reach requires local relevance
Advertisement
Related to this article
CORXEL’s Dr. Bo Liang on why efficacy is no longer obesity medicine's biggest gap — and the four unmet needs that define what comes next.
MRD Testing Is Becoming the Most Important Tool in Oncology Drug Development: Q&A with Eric Matthews
MRD testing is transforming oncology trials — compressing timelines, enriching populations, and generating earlier answers.
Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide sellers, and Avi Pardo flags a compliance blind spot in field teams' text messages with doctors.
Dr. Jeremy Levin joins Ken Banta to share why he believes biotech's future demands a new level of leadership and stakeholder education — and why "mission without method" is a wasted effort.
Real-world data from Novo's Octane study show patients who switched from injectable GLP-1 therapy to oral semaglutide lost an average of 4.1% of their body weight within three months.
Numerof's Michael Abrams on why directing employees to the most effective, economical clinicians is digital health's most valuable offering.
Life sciences spends billions on compliance — but WhatsApp, iMessage, and SMS conversations between field teams and HCPs remain invisible to oversight.
Advertisement
Advertisement
Trending on PharmExec
1
Novo Reports Real-World Data Showing Weight Loss After Switch to Oral Semaglutide Pill
2
Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics
3
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
4
As Peptide Rulemaking Stalls, FDA Enforcement Moves Forward
5